{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:02:33Z","timestamp":1791475353841,"version":"4.3.4"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,1,4]],"date-time":"2017-01-04T00:00:00Z","timestamp":1483488000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,1,4]],"date-time":"2017-01-04T00:00:00Z","timestamp":1483488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Current guidelines lack comprehensive information on the metastatic site-specific role of KRAS mutation in lung adenocarcinoma (LADC). We investigated the effect of KRAS mutation on overall survival (OS) in this setting. In our retrospective study, 500 consecutive Caucasian metastatic LADC patients with known KRAS mutational status were analyzed after excluding 32 patients with EGFR mutations. KRAS mutation incidence was 28.6%. The most frequent metastatic sites were lung (45.6%), bone (26.2%), adrenal gland (17.4%), brain (16.8%), pleura (15.6%) and liver (11%). Patients with intrapulmonary metastasis had significantly increased KRAS mutation frequency compared to those with extrapulmonary metastases (35% vs 26.5%, p\u2009=\u20090.0125). In contrast, pleural dissemination and liver involvement were associated with significantly decreased KRAS mutation incidence (vs all other metastatic sites; 17% (p\u2009&lt;\u20090.001) and 16% (p\u2009=\u20090.02) vs 33%, respectively). Strikingly, we found a significant prognostic effect of KRAS status only in the bone metastatic subcohort (KRAS-wild-type vs KRAS-mutant; median OS 9.7\u2009v 3.7 months; HR, 0.49; 95% CI, 0.31 to 0.79; p =\u20090.003). Our study suggests that KRAS mutation frequency in LADC patients shows a metastatic site dependent variation and, moreover, that the presence of KRAS mutation is associated with significantly worse outcome in bone metastatic cases.<\/jats:p>","DOI":"10.1038\/srep39721","type":"journal-article","created":{"date-parts":[[2017,1,4]],"date-time":"2017-01-04T10:15:31Z","timestamp":1483524931000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["KRAS-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: poor prognosis in patients with KRAS mutation and bone metastasis"],"prefix":"10.1038","volume":"7","author":[{"given":"Zoltan","family":"Lohinai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Klikovits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit","family":"Moldvay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyula","family":"Ostoros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erzsebet","family":"Raso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jozsef","family":"Timar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katalin","family":"Fabian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilona","family":"Kovalszky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Istv\u00e1n","family":"Kenessey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Aigner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferenc","family":"Renyi-Vamos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Klepetko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balazs","family":"Dome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balazs","family":"Hegedus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,1,4]]},"reference":[{"key":"BFsrep39721_CR1","first-page":"4682","volume":"49","author":"JL Bos","year":"1989","unstructured":"Bos, J. L. Ras Oncogenes in Human Cancer - a Review. Cancer Res 49, 4682\u20134689 (1989).","journal-title":"Cancer Res"},{"key":"BFsrep39721_CR2","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1158\/0008-5472.CAN-11-2612","volume":"72","author":"IA Prior","year":"2012","unstructured":"Prior, I. A., Lewis, P. D. & Mattos, C. A comprehensive survey of Ras mutations in cancer. Cancer Res 72, 2457\u20132467 (2012).","journal-title":"Cancer Res"},{"key":"BFsrep39721_CR3","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3816\/CLC.2006.n.030","volume":"8","author":"S Aviel-Ronen","year":"2006","unstructured":"Aviel-Ronen, S., Blackhall, F. H., Shepherd, F. A. & Tsao, M. S. K-ras mutations in non-small-cell lung carcinoma: A review. Clin Lung Cancer 8, 30\u201338 (2006).","journal-title":"Clin Lung Cancer"},{"key":"BFsrep39721_CR4","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1097\/JTO.0000000000000492","volume":"10","author":"Z Lohinai","year":"2015","unstructured":"Lohinai, Z. et al. Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 10, 738\u2013746 (2015).","journal-title":"Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer"},{"key":"BFsrep39721_CR5","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/j.ejca.2014.04.001","volume":"50","author":"M Cserepes","year":"2014","unstructured":"Cserepes, M. et al. Subtype-specific KRAS mutations in advanced lung adenocarcinoma: A retrospective study of patients treated with platinum-based chemotherapy. European journal of cancer 50, 1819\u20131828 (2014).","journal-title":"European journal of cancer"},{"key":"BFsrep39721_CR6","doi-asserted-by":"publisher","first-page":"828","DOI":"10.5858\/arpa.2012-0720-OA","volume":"137","author":"NI Lindeman","year":"2013","unstructured":"Lindeman, N. I. et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Archives of pathology & laboratory medicine 137, 828\u2013860 (2013).","journal-title":"Archives of pathology & laboratory medicine"},{"key":"BFsrep39721_CR7","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1200\/JCO.2008.19.8168","volume":"27","author":"A Jimeno","year":"2009","unstructured":"Jimeno, A., Messersmith, W. A., Hirsch, F. R., Franklin, W. A. & Eckhardt, S. G. KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 27, 1130\u20131136 (2009).","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"BFsrep39721_CR8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/annonc\/mdu378","volume":"26","author":"MJ Sorich","year":"2015","unstructured":"Sorich, M. J. et al. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann Oncol 26, 13\u201321 (2015).","journal-title":"Ann Oncol"},{"key":"BFsrep39721_CR9","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1002\/cncr.29196","volume":"121","author":"R Yaeger","year":"2015","unstructured":"Yaeger, R. et al. RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer. Cancer 121, 1195\u20131203 (2015).","journal-title":"Cancer"},{"key":"BFsrep39721_CR10","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1007\/s12032-014-0456-z","volume":"32","author":"F Petrelli","year":"2015","unstructured":"Petrelli, F. et al. Prognostic factors for survival with bevacizumab-based therapy in colorectal cancer patients: a systematic review and pooled analysis of 11,585 patients. Med Oncol 32, 456\u2013466 (2015).","journal-title":"Med Oncol"},{"key":"BFsrep39721_CR11","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1245\/s10434-014-4042-6","volume":"22","author":"Y Mise","year":"2015","unstructured":"Mise, Y. et al. RAS mutations predict radiologic and pathologic response in patients treated with chemotherapy before resection of colorectal liver metastases. Ann Surg Oncol 22, 834\u2013842 (2015).","journal-title":"Ann Surg Oncol"},{"key":"BFsrep39721_CR12","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s12032-014-0016-6","volume":"31","author":"K Zhu","year":"2014","unstructured":"Zhu, K. et al. Mutations of KRAS and PIK3CA as independent predictors of distant metastases in colorectal cancer. Med Oncol 31, 16\u201323 (2014).","journal-title":"Med Oncol"},{"key":"BFsrep39721_CR13","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1245\/s10434-013-3386-7","volume":"21","author":"T Schweiger","year":"2014","unstructured":"Schweiger, T. et al. EGFR, BRAF and KRAS status in patients undergoing pulmonary metastasectomy from primary colorectal carcinoma: a prospective follow-up study. Ann Surg Oncol 21, 946\u2013954 (2014).","journal-title":"Ann Surg Oncol"},{"key":"BFsrep39721_CR14","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1002\/bjs.8909","volume":"99","author":"S Stremitzer","year":"2012","unstructured":"Stremitzer, S. et al. KRAS status and outcome of liver resection after neoadjuvant chemotherapy including bevacizumab. Br J Surg 99, 1575\u20131582 (2012).","journal-title":"Br J Surg"},{"key":"BFsrep39721_CR15","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1245\/s10434-009-0605-3","volume":"17","author":"GM Nash","year":"2010","unstructured":"Nash, G. M. et al. KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastases. Ann Surg Oncol 17, 572\u2013578 (2010).","journal-title":"Ann Surg Oncol"},{"key":"BFsrep39721_CR16","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.critrevonc.2015.12.015","volume":"99","author":"F Passiglia","year":"2016","unstructured":"Passiglia, F. et al. Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis. Crit Rev Oncol Hematol 99, 150\u2013157 (2016).","journal-title":"Crit Rev Oncol Hematol"},{"key":"BFsrep39721_CR17","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1097\/JTO.0b013e318283d958","volume":"8","author":"P Martin","year":"2013","unstructured":"Martin, P., Leighl, N. B., Tsao, M. S. & Shepherd, F. A. KRAS Mutations as Prognostic and Predictive Markers in Non-Small Cell Lung Cancer. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 8, 530\u2013542 (2013).","journal-title":"Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer"},{"key":"BFsrep39721_CR18","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1038\/bjc.2015.327","volume":"113","author":"S Renaud","year":"2015","unstructured":"Renaud, S. et al. Prognostic value of the KRAS G12V mutation in 841 surgically resected Caucasian lung adenocarcinoma cases. British journal of cancer 113, 1206\u20131215 (2015).","journal-title":"British journal of cancer"},{"key":"BFsrep39721_CR19","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.jtho.2015.11.010","volume":"11","author":"A Zer","year":"2016","unstructured":"Zer, A. et al. Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Journal of thoracic oncology 11, 312\u2013323 (2016).","journal-title":"Journal of thoracic oncology"},{"key":"BFsrep39721_CR20","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/sj.bjc.6602258","volume":"92","author":"C Mascaux","year":"2005","unstructured":"Mascaux, C. et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. British journal of cancer 92, 131\u2013139 (2005).","journal-title":"British journal of cancer"},{"key":"BFsrep39721_CR21","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1056\/NEJM199008303230902","volume":"323","author":"RJ Slebos","year":"1990","unstructured":"Slebos, R. J. et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. The New England journal of medicine 323, 561\u2013565 (1990).","journal-title":"The New England journal of medicine"},{"key":"BFsrep39721_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2013.03.019","volume":"81","author":"D Meng","year":"2013","unstructured":"Meng, D. et al. Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: a systematic review with meta-analysis. Lung Cancer 81, 1\u201310 (2013).","journal-title":"Lung Cancer"},{"key":"BFsrep39721_CR23","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s12032-015-0489-y","volume":"32","author":"Y Zhang","year":"2015","unstructured":"Zhang, Y. et al. The efficacy of first-line chemotherapy is associated with KRAS mutation status in patients with advanced non-small cell lung cancer: a meta-analysis. Med Oncol 32, 61\u201372 (2015).","journal-title":"Med Oncol"},{"key":"BFsrep39721_CR24","doi-asserted-by":"publisher","first-page":"34014","DOI":"10.18632\/oncotarget.5607","volume":"6","author":"M Marabese","year":"2015","unstructured":"Marabese, M. et al. KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy. Oncotarget 6, 34014\u201334022 (2015).","journal-title":"Oncotarget"},{"key":"BFsrep39721_CR25","doi-asserted-by":"publisher","first-page":"e64816","DOI":"10.1371\/journal.pone.0064816","volume":"8","author":"JM Sun","year":"2013","unstructured":"Sun, J. M., Hwang, D. W., Ahn, J. S., Ahn, M. J. & Park, K. Prognostic and Predictive Value of KRAS Mutations in Advanced Non-Small Cell Lung Cancer. PLoS One 8, e64816, doi: 10.1371\/journal.pone.0064816 (2013).","journal-title":"PLoS One"},{"key":"BFsrep39721_CR26","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.cllc.2013.05.004","volume":"14","author":"X Dong","year":"2013","unstructured":"Dong, X. et al. Response to first-line chemotherapy in patients with non-small-cell lung cancer according to epidermal growth factor receptor and K-RAS mutation status. Clin Lung Cancer 14, 680\u2013687 (2013).","journal-title":"Clin Lung Cancer"},{"key":"BFsrep39721_CR27","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1097\/JTO.0b013e318298764e","volume":"8","author":"WW Mellema","year":"2013","unstructured":"Mellema, W. W. et al. KRAS mutations in advanced nonsquamous non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy have no predictive value. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 8, 1190\u20131195 (2013).","journal-title":"Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer"},{"key":"BFsrep39721_CR28","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/S1470-2045(11)70189-9","volume":"12","author":"KJ O\u2019Byrne","year":"2011","unstructured":"O\u2019Byrne, K. J. et al. Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. The Lancet. Oncology 12, 795\u2013805 (2011).","journal-title":"The Lancet. Oncology"},{"key":"BFsrep39721_CR29","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1002\/cncr.29313","volume":"121","author":"HA Yu","year":"2015","unstructured":"Yu, H. A. et al. Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomas. Cancer 121, 2078\u20132082 (2015).","journal-title":"Cancer"},{"key":"BFsrep39721_CR30","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2217\/fon.15.273","volume":"12","author":"S Renaud","year":"2016","unstructured":"Renaud, S. et al. Impact of EGFR mutations and KRAS amino acid substitution on the response to radiotherapy for brain metastasis of non-small-cell lung cancer. Future Oncol 12, 59\u201370 (2016).","journal-title":"Future Oncol"},{"key":"BFsrep39721_CR31","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.lungcan.2014.08.013","volume":"86","author":"N Zhao","year":"2014","unstructured":"Zhao, N. et al. Alterations of LKB1 and KRAS and risk of brain metastasis: comprehensive characterization by mutation analysis, copy number, and gene expression in non-small-cell lung carcinoma. Lung Cancer 86, 255\u2013261 (2014).","journal-title":"Lung Cancer"},{"key":"BFsrep39721_CR32","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1097\/JTO.0b013e31812f3c1a","volume":"2","author":"P Goldstraw","year":"2007","unstructured":"Goldstraw, P. et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 2, 706\u2013714 (2007).","journal-title":"Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer"},{"key":"BFsrep39721_CR33","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.oraloncology.2011.03.020","volume":"47","author":"B Szabo","year":"2011","unstructured":"Szabo, B. et al. Clinical significance of genetic alterations and expression of epidermal growth factor receptor (EGFR) in head and neck squamous cell carcinomas. Oral oncology 47, 487\u2013496 (2011).","journal-title":"Oral oncology"},{"key":"BFsrep39721_CR34","unstructured":"National Comprehensive Cancer Network. NCCN Guidelines Non-small cell lung cancer. Version 3.2017. https:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp (2016)."},{"key":"BFsrep39721_CR35","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/sj.bjc.6602258","volume":"92","author":"C Mascaux","year":"2005","unstructured":"Mascaux, C. et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. British journal of cancer 92, 131\u2013139 (2005).","journal-title":"British journal of cancer"},{"key":"BFsrep39721_CR36","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1634\/theoncologist.2015-0114","volume":"20","author":"BP Levy","year":"2015","unstructured":"Levy, B. P. et al. Molecular Testing for Treatment of Metastatic Non-Small Cell Lung Cancer: How to Implement Evidence-Based Recommendations. The oncologist 20, 1175\u20131181 (2015).","journal-title":"The oncologist"},{"key":"BFsrep39721_CR37","doi-asserted-by":"publisher","first-page":"4502","DOI":"10.1002\/cncr.27409","volume":"118","author":"RC Doebele","year":"2012","unstructured":"Doebele, R. C. et al. Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer. Cancer 118, 4502\u20134511 (2012).","journal-title":"Cancer"},{"key":"BFsrep39721_CR38","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.cllc.2014.06.006","volume":"15","author":"YY He","year":"2014","unstructured":"He, Y. Y. et al. Prognostic significance of genotype and number of metastatic sites in advanced non-small-cell lung cancer. Clin Lung Cancer 15, 441\u2013447 (2014).","journal-title":"Clin Lung Cancer"},{"key":"BFsrep39721_CR39","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1097\/JTO.0000000000000673","volume":"10","author":"WE Eberhardt","year":"2015","unstructured":"Eberhardt, W. E. et al. The IASLC Lung Cancer Staging Project: Proposals for the Revision of the M Descriptors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer. Journal of thoracic oncology 10, 1515\u20131522 (2015).","journal-title":"Journal of thoracic oncology"},{"key":"BFsrep39721_CR40","doi-asserted-by":"publisher","first-page":"6207","DOI":"10.1200\/JCO.2005.03.145","volume":"23","author":"CJ Langer","year":"2005","unstructured":"Langer, C. J. & Mehta, M. P. Current management of brain metastases, with a focus on systemic options. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 23, 6207\u20136219 (2005).","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"BFsrep39721_CR41","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1080\/02841860510029699","volume":"44","author":"L Kepka","year":"2005","unstructured":"Kepka, L., Cieslak, E., Bujko, K., Fijuth, J. & Wierzchowski, M. Results of the whole-brain radiotherapy for patients with brain metastases from lung cancer: the RTOG RPA intra-classes analysis. Acta oncologica 44, 389\u2013398 (2005).","journal-title":"Acta oncologica"},{"key":"BFsrep39721_CR42","doi-asserted-by":"publisher","first-page":"5900","DOI":"10.1200\/JCO.2005.02.857","volume":"23","author":"DA Eberhard","year":"2005","unstructured":"Eberhard, D. A. et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. Journal of Clinical Oncology 23, 5900\u20135909 (2005).","journal-title":"Journal of Clinical Oncology"},{"key":"BFsrep39721_CR43","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1097\/CAD.0b013e3283493160","volume":"22","author":"DP Modest","year":"2011","unstructured":"Modest, D. P. et al. Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status. Anti-cancer drugs 22, 913\u2013918 (2011).","journal-title":"Anti-cancer drugs"},{"key":"BFsrep39721_CR44","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/bonekey.2014.75","volume":"3","author":"CB Confavreux","year":"2014","unstructured":"Confavreux, C. B. et al. Mutational profiling of bone metastases from lung adenocarcinoma: results of a prospective study (POUMOS-TEC). BoneKEy reports 3, 580, doi: 10.1038\/bonekey.2014.75 (2014).","journal-title":"BoneKEy reports"},{"key":"BFsrep39721_CR45","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1007\/s12253-015-9955-2","volume":"21","author":"N Bittner","year":"2015","unstructured":"Bittner, N. et al. Bone Metastases and the EGFR and KRAS Mutation Status in Lung Adenocarcinoma-The Results of Three Year Retrospective Analysis. Pathology oncology research: POR 21, 1217\u20131221 (2015).","journal-title":"Pathology oncology research: POR"},{"key":"BFsrep39721_CR46","first-page":"2471","volume":"24","author":"A Tsunoda","year":"2004","unstructured":"Tsunoda, A. et al. Association of K-ras mutations with liver metastases from colorectal carcinoma. Anticancer research 24, 2471\u20132476 (2004).","journal-title":"Anticancer research"},{"key":"BFsrep39721_CR47","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1245\/s10434-012-2747-y","volume":"20","author":"K Watanabe","year":"2013","unstructured":"Watanabe, K. et al. Incidence and predictive factors for pulmonary metastases after curative resection of colon cancer. Ann Surg Oncol 20, 1374\u20131380 (2013).","journal-title":"Ann Surg Oncol"},{"key":"BFsrep39721_CR48","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/DCR.0b013e31821b9bf2","volume":"54","author":"K Watanabe","year":"2011","unstructured":"Watanabe, K. et al. Predictive factors for pulmonary metastases after curative resection of rectal cancer without preoperative chemoradiotherapy. Diseases of the colon and rectum 54, 989\u2013998 (2011).","journal-title":"Diseases of the colon and rectum"},{"key":"BFsrep39721_CR49","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1159\/000337426","volume":"21","author":"Y Varol","year":"2012","unstructured":"Varol, Y. et al. The frequency and significance of radiologically detected indeterminate pulmonary nodules in patients with colorectal cancer. Medical principles and practice: international journal of the Kuwait University, Health Science Centre 21, 457\u2013461 (2012).","journal-title":"Medical principles and practice: international journal of the Kuwait University, Health Science Centre"},{"key":"BFsrep39721_CR50","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1378\/chest.119.6.1635","volume":"119","author":"S Murin","year":"2001","unstructured":"Murin, S. & Inciardi, J. Cigarette smoking and the risk of pulmonary metastasis from breast cancer. Chest 119, 1635\u20131640 (2001).","journal-title":"Chest"},{"key":"BFsrep39721_CR51","first-page":"2707","volume":"17","author":"JA Abrams","year":"2008","unstructured":"Abrams, J. A., Lee, P. C., Port, J. L., Altorki, N. K. & Neugut, A. I. Cigarette smoking and risk of lung metastasis from esophageal cancer. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 17, 2707\u20132713 (2008).","journal-title":"Oncology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep39721.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep39721","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep39721.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,24]],"date-time":"2022-12-24T01:04:11Z","timestamp":1671843851000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep39721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,4]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,5,2]]}},"alternative-id":["BFsrep39721"],"URL":"https:\/\/doi.org\/10.1038\/srep39721","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,4]]},"assertion":[{"value":"16 September 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"39721"}}